Narrative Update on Mycronic: Analyst Price Target Revision
Analysts have revised their price target for Mycronic downward by SEK 31, from SEK 238 to SEK 207. This adjustment is based on updated forecasts for slower revenue growth and slightly softer profit margins.
What's in the News
- Mycronic secured an order for three mask writers from an existing customer in Asia. The order is valued between USD 48-52 million, with phased deliveries scheduled between Q2 2026 and Q1 2027 (Key Developments).
- An existing Asian customer placed an order for an SLX mask writer worth USD 5-7 million. Delivery is scheduled for Q2 2026 (Key Developments).
- Another SLX mask writer order from an existing Asian customer, valued at USD 3-5 million, will have net sales recognized in the current quarter (Key Developments).
Valuation Changes
- The consensus analyst price target has decreased from SEK 238 to SEK 207.
- The discount rate has increased slightly, from 6.10% to 6.24%.
- Revenue growth expectations have been revised downward, from 1.60% to 1.28%.
- The net profit margin is marginally lower, changing from 21.18% to 20.87%.
- The future P/E ratio has declined from 31.0x to 27.7x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.